Antileukotrienes in the treatment of bronchial asthma in children: expected and real success
https://doi.org/10.21518/2079-701X-2014-14-46-49
Abstract
The article summarizes current evidence on the role of leukotrienes in the pathogenesis of asthma in children and antileukotriene drugs in the treatment of the disease. Indications and prospects for the use of montelukast in the treatment of bronchial asthma in children are defined.
About the Author
Y. L. Mizernitsky
Clinical Research Institute of Pediatrics, Russian Medical Research University named after N.I. Pirogov, Moscow
Russian Federation
Russian Federation
References
1. Балаболкин И.И., Смирнов И.Е., Булгакова В.А., Горюнов А.В., Ларькова И.А. Современная концепция патогенеза бронхиальной астмы у детей. Иммунопатология, аллергология, инфектология, 2006, 1: 26-35.
2. Бронхиальная астма у детей (под ред. С.Ю. Каганова). М.: Медицина, 1999. 368.
3. Геппе Н.А., Колосова Н.Г К 15-летию первой Национальной программы по бронхиальной астме у детей. Пульмонология детского возраста: проблемы и решения (под ред. Мизерницкого Ю.Л., Царегородцева А.Д.). 2013, 13: 204-212.
4. Геппе Н.А., Фарбер И.М. Применение антагониста лейкотриеновых рецепторов монтелукаста для лечения бронхиальной астмы у детей первых лет жизни. Пульмонология, 2009, 5: 113-118.
5. Каганов С.Ю., Круглый Б.И., Сулаквилидзе И.В., Нестеренко В.Н., Святкина О.Б., Вельтищев Ю.Е. Аспириновая астма у детей. Педиатрия, 1988, 10: 56-60.
6. Княжеская Н.П. Антагонисты лейкотриеновых рецепторов - противовоспалительные препараты для лечения бронхиальной астмы. Consilium Medicum, 2013, 11: 13-16.
7. Мизерницкий Ю.Л. Бронхиальная астма. Хронические заболевания легких у детей (под ред. Розиновой Н.Н., Мизерницкого Ю.Л.). М.: «Практика», 2011: 149-168.
8. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 4-е изд., М., 2012, 108.
9. Тулуевская Л. Роль медиаторов липидной природы в патогенезе немедленной аллергии: Автореф. дис.. канд. биол. наук. М., 1992, 22.
10. Baek HS, Cho J, Kim JH, Oh JW, Lee HB. Ratio of leukotriene e(4) to exhaled nitric oxide and the therapeutic response in children with exercise-induced bronchoconstriction. Allergy Asthma Immunol Res., 2013, 5(1): 26-33.
11. Barnes N. Effects of antileukotrienes in the treatment of asthma. Am. J. Respir. Crit. Care Med., 2000, 161: 73-76.
12. Bisgaard H, Zielen S, Garcia-Garcia ML et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am. J. Respir. Crit. Care.Med., 2005, 171 (4): 315-322.
13. Byrne PM. Leukotriene bronchoconstriction induced by allergen and exercise. Am J Respir Crit Care Med, 2000, 161(suppl. ): 68-72.
14. Callero-Viera A, Infante S, Fuentes-Aparicio V, Zapatero L, Alonso-Lebrero E. Neuropsychiatry reactions to montelukast. JInvestigAllergol Clin Immunol, 2012, 22(6): 452-453.
15. Csoma Z, Kharitonov SA, Balint B et al. Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med, 2002, 166: 1345-1349.
16. Dockhorn RJ, Baumgartner RA, Leff JA et al. Comparison of the effects of intravenous and oral montelucast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax, 2000, 55: 260-265.
17. Fedberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J. Physiol, 1938, 94 (2): 187-226.
18. Henderson WRJr, Chiang GKS, Tien Y-T et al. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med, 2006, 173: 718-728.
19. Holgate S, Sampson A. Antileukotriene therapy. Am. J. Repir. Crit. Care Med, 2000, 161: 147-153.
20. Knorr B, Franchi LM, Bisgaard H et al. Montelukast, a leukotriene receptor antagonist, for the treatment of ent asthma in children aged 2 to 5 years. Pediatrics, 2001, 108 (3): 48.
21. Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in to children: a randomized trial. Pediatric Montelukast Study Group. JAMA, 1998, 279 (15): 1181-1186.
22. Kocyigit A, Gulcan Oksuz B, Yarar F, Uzun F, Igde M, Islek I. Hallucination development with montelukast in a child with asthma: case presentation. Iran J Allergy Asthma Immunol, 2013, 28, 12(4): 397-399.
23. Massingham K, Fox S, Smaldone A. Asthma therapy in pediatric patients: a systematic review of treatment with montelukast versus inhaled corticosteroids. JPediatrHealth Care. 2014, 28(1): 51-62.
24. Pauwels RA, Joos GF, Kips JC. Leukotrienes as therapeutic target in asthma. Allergy 1995, 50: 615-622.
25. Pizzichini E, Leff JA, Reiss TF et al. Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. Eur Respir J, 1999, 14: 12-18.
26. Scadding GW, Scadding GK. Recent advances in antileukotriene therapy Curr Opin Allergy Clin Immunol. 2010, 10(4): 370-376.
27. Stanford RH, Shah M, Chaudhari SL Clinical and economic outcomes associated with low-dose fluticasone propionate versus montelukast inchildren with asthma aged 4 to 11 years. Open Respir Med J. 2012, 6: 37-43.
28. Szczeklik A, Stevenson D. Aspirin-induced asthma: advances in pathogenesis and management. J. Allergy Clin. Immunol. 1999, 104: 5-13.
29. Visitsunthorn N, Chirdjirapong V, Santadilog S, Pajarn P, Jirapongsananuruk O, Komoltri C, Vichyanon P. The effect of montelukast on bronchial hyperreactivity and lung function in asthmatic children aged 6-13 years. Asian Pac J Allergy Immunol, 2011, 29(2): 127-133.
30. Wahn U, Dass SB. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clin Ther, 2008, 30: 1026-1035.
Review
For citations:
Mizernitsky YL. Antileukotrienes in the treatment of bronchial asthma in children: expected and real success. Meditsinskiy sovet = Medical Council. 2014;(14):46-49. (In Russ.) https://doi.org/10.21518/2079-701X-2014-14-46-49
Views:
727
Email this article 